Review





Similar Products

gene exp nr4a1 mm01300401 m1  (Thermo Fisher)
99
Thermo Fisher gene exp nr4a1 mm01300401 m1
Gene Exp Nr4a1 Mm01300401 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp nr4a1 mm01300401 m1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp nr4a1 mm01300401 m1 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
a9 induced nr4a1 crbn co immunoprecipitation  (Sino Biological)
94
Sino Biological a9 induced nr4a1 crbn co immunoprecipitation
A9 Induced Nr4a1 Crbn Co Immunoprecipitation, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a9 induced nr4a1 crbn co immunoprecipitation/product/Sino Biological
Average 94 stars, based on 1 article reviews
a9 induced nr4a1 crbn co immunoprecipitation - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
gene exp nr4a1 hs00374226 m1  (Thermo Fisher)
96
Thermo Fisher gene exp nr4a1 hs00374226 m1
(A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , <t>NR4A1</t> , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Gene Exp Nr4a1 Hs00374226 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp nr4a1 hs00374226 m1/product/Thermo Fisher
Average 96 stars, based on 1 article reviews
gene exp nr4a1 hs00374226 m1 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
gene exp nr4a1 mm00439358 m1  (Thermo Fisher)
94
Thermo Fisher gene exp nr4a1 mm00439358 m1
(A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , <t>NR4A1</t> , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Gene Exp Nr4a1 Mm00439358 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp nr4a1 mm00439358 m1/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
gene exp nr4a1 mm00439358 m1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
flag nr4a1  (Sino Biological)
94
Sino Biological flag nr4a1
(A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , <t>NR4A1</t> , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Flag Nr4a1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flag nr4a1/product/Sino Biological
Average 94 stars, based on 1 article reviews
flag nr4a1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
nr4a1  (Sino Biological)
94
Sino Biological nr4a1
(A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , <t>NR4A1</t> , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Nr4a1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nr4a1/product/Sino Biological
Average 94 stars, based on 1 article reviews
nr4a1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
c flag tagged mouse nr4a1  (Sino Biological)
94
Sino Biological c flag tagged mouse nr4a1
(A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , <t>NR4A1</t> , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
C Flag Tagged Mouse Nr4a1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c flag tagged mouse nr4a1/product/Sino Biological
Average 94 stars, based on 1 article reviews
c flag tagged mouse nr4a1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
nr4a1 gene  (Thermo Fisher)
90
Thermo Fisher nr4a1 gene
(A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , <t>NR4A1</t> , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Nr4a1 Gene, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nr4a1 gene/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
nr4a1 gene - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , NR4A1 , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: bioRxiv

Article Title: Functionally Mature Bioengineered Human Skeletal Muscle Tissues Capture Essential Aspects of Glucose Metabolism

doi: 10.64898/2026.01.16.698404

Figure Lengend Snippet: (A) Effect of acute treatment with clenbuterol (10 nM, 20 min) on phosphorylation of β-adrenergic (B2AR) downstream targets including HSL (Ser660), CREB (Ser133), and RPS6 (Ser235/236) (n=4). (B) Gene expression of B2AR–responsive transcripts ( PPARGC1A , NR4A3 , NR4A1 , PGK1 , GYS1 , and others) after chronic clenbuterol treatment at the indicated doses (n=5). (C) Maximal tetanic force measured over time in tissues exposed to increasing clenbuterol concentrations (0.2–10 nM). Right: day-7 maximal force relative to vehicle for each dose (n=3). (D) Representative confocal images of myofibrillar structure in vehicle- and clenbuterol-treated tissues (n=2) (E) Maximal tetanic force during an inactivity protocol with or without clenbuterol treatment. Left: force traces over the detraining period. Right: day-7 maximal force in vehicle versus clenbuterol-treated groups (n=5). (F) Fatigue development during repeated contractions (protocol 2) in glucose-containing media in control versus clenbuterol-treated tissues. Inset: endurance values at the end of the protocol (n=5). (G) Fatigue development during repeated contractions (protocol 2) in glucose-free media in control versus clenbuterol-treated tissues (n=5). Data are presented as mean ± SEM, with individual values shown where applicable. Statistical comparisons were performed using one-way or two-way ANOVA with appropriate multiple-comparisons correction. ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The following primers were used: TaqMan Gene Expression Assays (ThermoFisher Cat# 4331182), with the following ID numbers: GYS1: ID Hs00157863_m1, Ppargc1a: ID Hs00173304_m1, Nr4a3: ID Hs00545009_g1, Nr4a1: ID Hs00374226_m1 and Pgk1: ID Hs00943178_g1.

Techniques: Phospho-proteomics, Gene Expression, Control